Silexion Therapeutics Corp financial data

Symbol
SLXN, SLXNW on Nasdaq
Location
Ramat Gan, Israel
Fiscal year end
31 December
Latest financial report
17 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 304% %
Debt-to-equity 168% %
Return On Equity -388% % -140%
Return On Assets -145% % 74%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3,330,785,000 shares 38218%
Common Stock, Shares, Outstanding 3,126,642 shares -72%
Entity Public Float $0 USD
Common Stock, Value, Issued $42,000 USD 2000%
Weighted Average Number of Shares Outstanding, Basic 1,329,515 shares 3093%
Weighted Average Number of Shares Outstanding, Diluted 1,329,515 shares 3093%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $7,140,000 USD 23%
General and Administrative Expense $4,492,000 USD -34%
Operating Income (Loss) $11,632,000 USD 7.5%
Nonoperating Income (Expense) $277,000 USD -93%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $11,909,000 USD 28%
Income Tax Expense (Benefit) $0 USD -100%
Net Income (Loss) Attributable to Parent $11,912,000 USD 28%
Earnings Per Share, Basic 8.96 USD/shares -98%
Earnings Per Share, Diluted 8.96 USD/shares -98%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $5,991,000 USD 405%
Other Assets, Current $49,000 USD -21%
Assets, Current $6,637,000 USD 195%
Property, Plant and Equipment, Net $25,000 USD -17%
Operating Lease, Right-of-Use Asset $412,000 USD -22%
Assets $7,215,000 USD 152%
Accounts Payable, Current $787,000 USD -15%
Employee-related Liabilities, Current $879,000 USD 37%
Liabilities, Current $2,758,000 USD -22%
Operating Lease, Liability, Noncurrent $286,000 USD -22%
Liabilities $4,612,000 USD -33%
Retained Earnings (Accumulated Deficit) $55,166,000 USD -28%
Stockholders' Equity Attributable to Parent $2,603,000 USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $2,603,000 USD
Liabilities and Equity $7,215,000 USD 152%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $10,819,000 USD -29%
Net Cash Provided by (Used in) Financing Activities $15,640,000 USD
Net Cash Provided by (Used in) Investing Activities $14,000 USD 36%
Common Stock, Shares Authorized 9,000,000 shares -96%
Common Stock, Shares, Issued 3,126,642 shares -72%
Common Stock, Par or Stated Value Per Share 0.0135 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $6,075,000 USD 378%
Interest Paid, Excluding Capitalized Interest, Operating Activities $13,000 USD -52%
Deferred Tax Assets, Valuation Allowance $9,851,000 USD 43%
Deferred Tax Assets, Gross $9,946,000 USD 42%
Operating Lease, Liability $468,000 USD -11%
Depreciation $14,000 USD -44%
Payments to Acquire Property, Plant, and Equipment $9,000 USD -59%
Lessee, Operating Lease, Liability, to be Paid $538,000 USD -15%
Property, Plant and Equipment, Gross $108,000 USD 9.1%
Operating Lease, Liability, Current $182,000 USD 15%
Lessee, Operating Lease, Liability, to be Paid, Year Two $197,000 USD 18%
Lessee, Operating Lease, Liability, to be Paid, Year One $191,000 USD 16%
Operating Lease, Weighted Average Discount Rate, Percent 0.1128 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $70,000 USD -36%
Lessee, Operating Lease, Liability, to be Paid, Year Three $150,000 USD -13%
Deferred Tax Assets, Operating Loss Carryforwards $8,111,000 USD 40%
Additional Paid in Capital $57,727,000 USD 47%
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $134,000 USD -98%